human igfbp2 rhigfbp2 protein Search Results


recombinant human igfbp 2  (R&D Systems)
94
R&D Systems recombinant human igfbp 2
Recombinant Human Igfbp 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+igfbp2+rhigfbp2+protein/pm15095286-52-69-74?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
recombinant human igfbp 2 - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
human igfbp2 rhigfbp2 protein  (R&D Systems)
94
R&D Systems human igfbp2 rhigfbp2 protein
<t>IGFBP2</t> contributes to the high antitumor efficacy of MEK inhibitor-trametinib and RTK inhibitor-anlotinib combination treatments. a , b Angiogenesis-related protein chip analyses ( a ) and related statistical quantification ( b ) of A549 cells after 24 h of trametinib (10 nM), anlotinib (1 μM) or combination treatment. c , d Western blot analyses ( c ) and related statistical analyses ( d ) of the IGFBP2 levels in A549 and H23 cells after 48 h of trametinib (10 nM), anlotinib (1 μM) or combination treatment. n = 3. e Immunofluorescence analyses of IGFBP2 levels in A549 and H460 xenograft tumors. Scale bar: 50 μm. n = 5. f , g Invasion analyses of A549 and H23 cells treated with trametinib plus anlotinib, IGFBP2, or both for 24 h ( f ) and related statistical analyses ( g ). Scale bar: 50 μm. n = 3. h Viability of A549 and H23 cells treated with trametinib plus anlotinib, IGFBP2 or both for 24 h. n = 3. i ‒ l RT‒PCR quantification of IGFBP2 ( i ), CCND1 ( j ), CCNE2 ( k ), and c-MYC ( l ) mRNA levels in A549 and H23 cells upon IGFBP2 knockdown. n = 3. m, n Western blot analyses of c-MYC levels in A549 cells treated with trametinib plus anlotinib or supplemented with IGFBP2 for 24 h ( m ) and related statistical analyses ( n ). n = 3. o Western blot analyses of RTK expression in A549 and H23 cells treated with trametinib plus anlotinib or supplemented with IGFBP2 for 10 days. Statistical analyses were performed via two-tailed Student’s t test. The data are presented as the means ± SEMs. *P < 0.05, **P < 0.01, ***P < 0.001
Human Igfbp2 Rhigfbp2 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+igfbp2+rhigfbp2+protein/pmc12426211-332-2-9?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
human igfbp2 rhigfbp2 protein - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
porcine insulin  (Chemie GmbH)
90
Chemie GmbH porcine insulin
<t>IGFBP2</t> contributes to the high antitumor efficacy of MEK inhibitor-trametinib and RTK inhibitor-anlotinib combination treatments. a , b Angiogenesis-related protein chip analyses ( a ) and related statistical quantification ( b ) of A549 cells after 24 h of trametinib (10 nM), anlotinib (1 μM) or combination treatment. c , d Western blot analyses ( c ) and related statistical analyses ( d ) of the IGFBP2 levels in A549 and H23 cells after 48 h of trametinib (10 nM), anlotinib (1 μM) or combination treatment. n = 3. e Immunofluorescence analyses of IGFBP2 levels in A549 and H460 xenograft tumors. Scale bar: 50 μm. n = 5. f , g Invasion analyses of A549 and H23 cells treated with trametinib plus anlotinib, IGFBP2, or both for 24 h ( f ) and related statistical analyses ( g ). Scale bar: 50 μm. n = 3. h Viability of A549 and H23 cells treated with trametinib plus anlotinib, IGFBP2 or both for 24 h. n = 3. i ‒ l RT‒PCR quantification of IGFBP2 ( i ), CCND1 ( j ), CCNE2 ( k ), and c-MYC ( l ) mRNA levels in A549 and H23 cells upon IGFBP2 knockdown. n = 3. m, n Western blot analyses of c-MYC levels in A549 cells treated with trametinib plus anlotinib or supplemented with IGFBP2 for 24 h ( m ) and related statistical analyses ( n ). n = 3. o Western blot analyses of RTK expression in A549 and H23 cells treated with trametinib plus anlotinib or supplemented with IGFBP2 for 10 days. Statistical analyses were performed via two-tailed Student’s t test. The data are presented as the means ± SEMs. *P < 0.05, **P < 0.01, ***P < 0.001
Porcine Insulin, supplied by Chemie GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+igfbp2+rhigfbp2+protein/pm15095286-52-69-60?v=Chemie+GmbH
Average 90 stars, based on 1 article reviews
porcine insulin - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
igfbp-2 assay reagent  (GroPep Bioreagents)
90
GroPep Bioreagents igfbp-2 assay reagent
<t>IGFBP2</t> contributes to the high antitumor efficacy of MEK inhibitor-trametinib and RTK inhibitor-anlotinib combination treatments. a , b Angiogenesis-related protein chip analyses ( a ) and related statistical quantification ( b ) of A549 cells after 24 h of trametinib (10 nM), anlotinib (1 μM) or combination treatment. c , d Western blot analyses ( c ) and related statistical analyses ( d ) of the IGFBP2 levels in A549 and H23 cells after 48 h of trametinib (10 nM), anlotinib (1 μM) or combination treatment. n = 3. e Immunofluorescence analyses of IGFBP2 levels in A549 and H460 xenograft tumors. Scale bar: 50 μm. n = 5. f , g Invasion analyses of A549 and H23 cells treated with trametinib plus anlotinib, IGFBP2, or both for 24 h ( f ) and related statistical analyses ( g ). Scale bar: 50 μm. n = 3. h Viability of A549 and H23 cells treated with trametinib plus anlotinib, IGFBP2 or both for 24 h. n = 3. i ‒ l RT‒PCR quantification of IGFBP2 ( i ), CCND1 ( j ), CCNE2 ( k ), and c-MYC ( l ) mRNA levels in A549 and H23 cells upon IGFBP2 knockdown. n = 3. m, n Western blot analyses of c-MYC levels in A549 cells treated with trametinib plus anlotinib or supplemented with IGFBP2 for 24 h ( m ) and related statistical analyses ( n ). n = 3. o Western blot analyses of RTK expression in A549 and H23 cells treated with trametinib plus anlotinib or supplemented with IGFBP2 for 10 days. Statistical analyses were performed via two-tailed Student’s t test. The data are presented as the means ± SEMs. *P < 0.05, **P < 0.01, ***P < 0.001
Igfbp 2 Assay Reagent, supplied by GroPep Bioreagents, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+igfbp2+rhigfbp2+protein/pm17348863-45-4-19?v=GroPep+Bioreagents
Average 90 stars, based on 1 article reviews
igfbp-2 assay reagent - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
recombinant human (rh) igfbp-2  (GroPep Bioreagents)
90
GroPep Bioreagents recombinant human (rh) igfbp-2
<t>IGFBP2</t> contributes to the high antitumor efficacy of MEK inhibitor-trametinib and RTK inhibitor-anlotinib combination treatments. a , b Angiogenesis-related protein chip analyses ( a ) and related statistical quantification ( b ) of A549 cells after 24 h of trametinib (10 nM), anlotinib (1 μM) or combination treatment. c , d Western blot analyses ( c ) and related statistical analyses ( d ) of the IGFBP2 levels in A549 and H23 cells after 48 h of trametinib (10 nM), anlotinib (1 μM) or combination treatment. n = 3. e Immunofluorescence analyses of IGFBP2 levels in A549 and H460 xenograft tumors. Scale bar: 50 μm. n = 5. f , g Invasion analyses of A549 and H23 cells treated with trametinib plus anlotinib, IGFBP2, or both for 24 h ( f ) and related statistical analyses ( g ). Scale bar: 50 μm. n = 3. h Viability of A549 and H23 cells treated with trametinib plus anlotinib, IGFBP2 or both for 24 h. n = 3. i ‒ l RT‒PCR quantification of IGFBP2 ( i ), CCND1 ( j ), CCNE2 ( k ), and c-MYC ( l ) mRNA levels in A549 and H23 cells upon IGFBP2 knockdown. n = 3. m, n Western blot analyses of c-MYC levels in A549 cells treated with trametinib plus anlotinib or supplemented with IGFBP2 for 24 h ( m ) and related statistical analyses ( n ). n = 3. o Western blot analyses of RTK expression in A549 and H23 cells treated with trametinib plus anlotinib or supplemented with IGFBP2 for 10 days. Statistical analyses were performed via two-tailed Student’s t test. The data are presented as the means ± SEMs. *P < 0.05, **P < 0.01, ***P < 0.001
Recombinant Human (Rh) Igfbp 2, supplied by GroPep Bioreagents, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+igfbp2+rhigfbp2+protein/pm20061427-77-0-4?v=GroPep+Bioreagents
Average 90 stars, based on 1 article reviews
recombinant human (rh) igfbp-2 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
recombinant human igf-1  (GroPep Bioreagents)
90
GroPep Bioreagents recombinant human igf-1
<t>IGFBP2</t> contributes to the high antitumor efficacy of MEK inhibitor-trametinib and RTK inhibitor-anlotinib combination treatments. a , b Angiogenesis-related protein chip analyses ( a ) and related statistical quantification ( b ) of A549 cells after 24 h of trametinib (10 nM), anlotinib (1 μM) or combination treatment. c , d Western blot analyses ( c ) and related statistical analyses ( d ) of the IGFBP2 levels in A549 and H23 cells after 48 h of trametinib (10 nM), anlotinib (1 μM) or combination treatment. n = 3. e Immunofluorescence analyses of IGFBP2 levels in A549 and H460 xenograft tumors. Scale bar: 50 μm. n = 5. f , g Invasion analyses of A549 and H23 cells treated with trametinib plus anlotinib, IGFBP2, or both for 24 h ( f ) and related statistical analyses ( g ). Scale bar: 50 μm. n = 3. h Viability of A549 and H23 cells treated with trametinib plus anlotinib, IGFBP2 or both for 24 h. n = 3. i ‒ l RT‒PCR quantification of IGFBP2 ( i ), CCND1 ( j ), CCNE2 ( k ), and c-MYC ( l ) mRNA levels in A549 and H23 cells upon IGFBP2 knockdown. n = 3. m, n Western blot analyses of c-MYC levels in A549 cells treated with trametinib plus anlotinib or supplemented with IGFBP2 for 24 h ( m ) and related statistical analyses ( n ). n = 3. o Western blot analyses of RTK expression in A549 and H23 cells treated with trametinib plus anlotinib or supplemented with IGFBP2 for 10 days. Statistical analyses were performed via two-tailed Student’s t test. The data are presented as the means ± SEMs. *P < 0.05, **P < 0.01, ***P < 0.001
Recombinant Human Igf 1, supplied by GroPep Bioreagents, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+igfbp2+rhigfbp2+protein/pm17348863-45-0-19?v=GroPep+Bioreagents
Average 90 stars, based on 1 article reviews
recombinant human igf-1 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
igfbp-4 assay reagent  (GroPep Bioreagents)
90
GroPep Bioreagents igfbp-4 assay reagent
<t>IGFBP2</t> contributes to the high antitumor efficacy of MEK inhibitor-trametinib and RTK inhibitor-anlotinib combination treatments. a , b Angiogenesis-related protein chip analyses ( a ) and related statistical quantification ( b ) of A549 cells after 24 h of trametinib (10 nM), anlotinib (1 μM) or combination treatment. c , d Western blot analyses ( c ) and related statistical analyses ( d ) of the IGFBP2 levels in A549 and H23 cells after 48 h of trametinib (10 nM), anlotinib (1 μM) or combination treatment. n = 3. e Immunofluorescence analyses of IGFBP2 levels in A549 and H460 xenograft tumors. Scale bar: 50 μm. n = 5. f , g Invasion analyses of A549 and H23 cells treated with trametinib plus anlotinib, IGFBP2, or both for 24 h ( f ) and related statistical analyses ( g ). Scale bar: 50 μm. n = 3. h Viability of A549 and H23 cells treated with trametinib plus anlotinib, IGFBP2 or both for 24 h. n = 3. i ‒ l RT‒PCR quantification of IGFBP2 ( i ), CCND1 ( j ), CCNE2 ( k ), and c-MYC ( l ) mRNA levels in A549 and H23 cells upon IGFBP2 knockdown. n = 3. m, n Western blot analyses of c-MYC levels in A549 cells treated with trametinib plus anlotinib or supplemented with IGFBP2 for 24 h ( m ) and related statistical analyses ( n ). n = 3. o Western blot analyses of RTK expression in A549 and H23 cells treated with trametinib plus anlotinib or supplemented with IGFBP2 for 10 days. Statistical analyses were performed via two-tailed Student’s t test. The data are presented as the means ± SEMs. *P < 0.05, **P < 0.01, ***P < 0.001
Igfbp 4 Assay Reagent, supplied by GroPep Bioreagents, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+igfbp2+rhigfbp2+protein/pm17348863-45-7-19?v=GroPep+Bioreagents
Average 90 stars, based on 1 article reviews
igfbp-4 assay reagent - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
collagenase type i  (Chemie GmbH)
90
Chemie GmbH collagenase type i
<t>IGFBP2</t> contributes to the high antitumor efficacy of MEK inhibitor-trametinib and RTK inhibitor-anlotinib combination treatments. a , b Angiogenesis-related protein chip analyses ( a ) and related statistical quantification ( b ) of A549 cells after 24 h of trametinib (10 nM), anlotinib (1 μM) or combination treatment. c , d Western blot analyses ( c ) and related statistical analyses ( d ) of the IGFBP2 levels in A549 and H23 cells after 48 h of trametinib (10 nM), anlotinib (1 μM) or combination treatment. n = 3. e Immunofluorescence analyses of IGFBP2 levels in A549 and H460 xenograft tumors. Scale bar: 50 μm. n = 5. f , g Invasion analyses of A549 and H23 cells treated with trametinib plus anlotinib, IGFBP2, or both for 24 h ( f ) and related statistical analyses ( g ). Scale bar: 50 μm. n = 3. h Viability of A549 and H23 cells treated with trametinib plus anlotinib, IGFBP2 or both for 24 h. n = 3. i ‒ l RT‒PCR quantification of IGFBP2 ( i ), CCND1 ( j ), CCNE2 ( k ), and c-MYC ( l ) mRNA levels in A549 and H23 cells upon IGFBP2 knockdown. n = 3. m, n Western blot analyses of c-MYC levels in A549 cells treated with trametinib plus anlotinib or supplemented with IGFBP2 for 24 h ( m ) and related statistical analyses ( n ). n = 3. o Western blot analyses of RTK expression in A549 and H23 cells treated with trametinib plus anlotinib or supplemented with IGFBP2 for 10 days. Statistical analyses were performed via two-tailed Student’s t test. The data are presented as the means ± SEMs. *P < 0.05, **P < 0.01, ***P < 0.001
Collagenase Type I, supplied by Chemie GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+igfbp2+rhigfbp2+protein/pm15095286-52-47-60?v=Chemie+GmbH
Average 90 stars, based on 1 article reviews
collagenase type i - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


IGFBP2 contributes to the high antitumor efficacy of MEK inhibitor-trametinib and RTK inhibitor-anlotinib combination treatments. a , b Angiogenesis-related protein chip analyses ( a ) and related statistical quantification ( b ) of A549 cells after 24 h of trametinib (10 nM), anlotinib (1 μM) or combination treatment. c , d Western blot analyses ( c ) and related statistical analyses ( d ) of the IGFBP2 levels in A549 and H23 cells after 48 h of trametinib (10 nM), anlotinib (1 μM) or combination treatment. n = 3. e Immunofluorescence analyses of IGFBP2 levels in A549 and H460 xenograft tumors. Scale bar: 50 μm. n = 5. f , g Invasion analyses of A549 and H23 cells treated with trametinib plus anlotinib, IGFBP2, or both for 24 h ( f ) and related statistical analyses ( g ). Scale bar: 50 μm. n = 3. h Viability of A549 and H23 cells treated with trametinib plus anlotinib, IGFBP2 or both for 24 h. n = 3. i ‒ l RT‒PCR quantification of IGFBP2 ( i ), CCND1 ( j ), CCNE2 ( k ), and c-MYC ( l ) mRNA levels in A549 and H23 cells upon IGFBP2 knockdown. n = 3. m, n Western blot analyses of c-MYC levels in A549 cells treated with trametinib plus anlotinib or supplemented with IGFBP2 for 24 h ( m ) and related statistical analyses ( n ). n = 3. o Western blot analyses of RTK expression in A549 and H23 cells treated with trametinib plus anlotinib or supplemented with IGFBP2 for 10 days. Statistical analyses were performed via two-tailed Student’s t test. The data are presented as the means ± SEMs. *P < 0.05, **P < 0.01, ***P < 0.001

Journal: Signal Transduction and Targeted Therapy

Article Title: Coinhibition of the MEK/RTK pathway has high therapeutic efficacy in KRAS-mutant non-small cell lung cancer

doi: 10.1038/s41392-025-02382-w

Figure Lengend Snippet: IGFBP2 contributes to the high antitumor efficacy of MEK inhibitor-trametinib and RTK inhibitor-anlotinib combination treatments. a , b Angiogenesis-related protein chip analyses ( a ) and related statistical quantification ( b ) of A549 cells after 24 h of trametinib (10 nM), anlotinib (1 μM) or combination treatment. c , d Western blot analyses ( c ) and related statistical analyses ( d ) of the IGFBP2 levels in A549 and H23 cells after 48 h of trametinib (10 nM), anlotinib (1 μM) or combination treatment. n = 3. e Immunofluorescence analyses of IGFBP2 levels in A549 and H460 xenograft tumors. Scale bar: 50 μm. n = 5. f , g Invasion analyses of A549 and H23 cells treated with trametinib plus anlotinib, IGFBP2, or both for 24 h ( f ) and related statistical analyses ( g ). Scale bar: 50 μm. n = 3. h Viability of A549 and H23 cells treated with trametinib plus anlotinib, IGFBP2 or both for 24 h. n = 3. i ‒ l RT‒PCR quantification of IGFBP2 ( i ), CCND1 ( j ), CCNE2 ( k ), and c-MYC ( l ) mRNA levels in A549 and H23 cells upon IGFBP2 knockdown. n = 3. m, n Western blot analyses of c-MYC levels in A549 cells treated with trametinib plus anlotinib or supplemented with IGFBP2 for 24 h ( m ) and related statistical analyses ( n ). n = 3. o Western blot analyses of RTK expression in A549 and H23 cells treated with trametinib plus anlotinib or supplemented with IGFBP2 for 10 days. Statistical analyses were performed via two-tailed Student’s t test. The data are presented as the means ± SEMs. *P < 0.05, **P < 0.01, ***P < 0.001

Article Snippet: The recombinant human IGFBP2 (rhIGFBP2) protein was purchased from R&D Systems (Cat. 674-B2-025).

Techniques: Western Blot, Immunofluorescence, Knockdown, Expressing, Two Tailed Test